The ERISA Industry Committee (ERIC) today offered improvements to a proposed U.S. Department of Labor (DOL) rule so that large plan sponsors will still be able to provide meaningful benefits to tens of millions of working Americans.
Miscellaneous Archives:
The ERISA Industry Committee Commends Congress for Passing the Lower Costs, More Transparency Act
WASHINGTON – December 13, 2023 – The ERISA Industry Committee (ERIC) commended the House of Representatives for passing the Lower Costs, More Transparency Act (H.R. 5378), a bipartisan bill aimed at providing more transparency to the U.S. health care system.
The ERISA Industry Committee President and CEO James Gelfand Named a Top Lobbyist by The Hill
WASHINGTON, December 6, 2023 – The ERISA Industry Committee (ERIC) today announced that its President and CEO James Gelfand has been named one of The Hill’s Top Lobbyists, in the association category, by The Hill, a daily online and published source of national political news and information.
The ERISA Industry Committee Supports Coverage of Over-the-Counter Preventive Items and Services
WASHINGTON – December 4, 2023 – The ERISA Industry Committee (ERIC) today said it supports coverage of over-the-counter (OTC) preventive items and services – including contraceptive items and services – provided they are of high-quality and are clinically proven to improve health outcomes.
The ERISA Industry Committee Urges Oregon Employment Department to Amend Rules Implementing Paid Leave Oregon Program
WASHINGTON, November 30, 2023 – In comments submitted today to the Oregon Employment Department, The ERISA Industry Committee (ERIC) recommended key provisions of proposed permanent regulations contained in “Paid Leave Oregon – Batch 9 – Appeals, Assistance Grants, Benefits, Confidentiality, Equivalent Plans, and Self-employment” be amended or developed further to prevent unnecessary compliance complications and better facilitate coordination of overlapping benefits.
The ERISA Industry Committee to Co-Host ERISA 50th Anniversary Symposium and Gala
WASHINGTON – November 30, 2023 – The ERISA Industry Committee (ERIC) announced that it and eight associations will host the ERISA 50th Anniversary Symposium and Gala on Thursday, September 12, 2024, to mark five decades since the landmark law’s passage.
ERIC and EmployersRx Urge Congress to Pass PBM Reforms
WASHINGTON, November 17, 2023 — The ERISA Industry Committee (ERIC) and Employers’ Prescription for Affordable Drugs (EmployersRx), a coalition of employers formed in 2019 to advocate for policies that address the high cost of prescription drugs, along with 50 other organizations representing employers, patients, and a wide range of industry sectors, calls on Congress to pass strong pharmacy benefit manager (PBM) reforms this year to address rising health care costs.
The ERISA Industry Committee Says Congress Should Reexamine Premiums Paid by Retirement Pension Plan Sponsors
WASHINGTON – November 16, 2023 – The ERISA Industry Committee (ERIC) said today that the $44.6 billion surplus in the Pension Benefit Guaranty Corporation’s (PBGC) single-employer insurance program, detailed in the agency’s Fiscal Year 2023 Annual Report, should lead Congress to reexamine the premiums paid by companies that sponsor defined benefit pension plans.
ERIC President and CEO James Gelfand Named a Top Lobbyist of 2023
WASHINGTON, November 14, 2023 – The ERISA Industry Committee (ERIC) today announced that its president and CEO James Gelfand has been named one of the top 100 lobbyists in the U.S. by the National Institute for Lobbying & Ethics (NILE), an organization representing lobbying, public policy, and government affairs professionals.
The ERISA Industry Committee Asks Ohio Legislature to Recognize Value of Proven Biosimilar Products
WASHINGTON, November 1, 2023 – The ERISA Industry Committee (ERIC) today submitted a comment letter to the Ohio House of Representatives Insurance Committee urging the panel to amend House Bill 291 to include access to all biosimilar products, a necessary step to ensure that the bill will promote competition, and drive lower drug costs for Ohioans.